96149-05-2

Usage

Uses

Used in Pharmaceutical Industry:
(1S)-(+)-Dimethyl succinate is used as a chemical intermediate for the production of pharmaceuticals. Its role in this industry is pivotal as it aids in the synthesis of various medicinal compounds, contributing to the development of new drugs and therapies.
Used in Perfumery:
In the perfume industry, (1S)-(+)-Dimethyl succinate is utilized as a component in the creation of fragrances. Its fruity scent makes it a valuable addition to the formulation of perfumes, enhancing the olfactory experience of consumers.
Used in Flavorings:
(1S)-(+)-Dimethyl succinate also finds application in the flavor industry, where it is used to impart specific tastes to food products and beverages. Its fruity odor makes it suitable for creating natural and appealing flavors.
Used as a Solvent:
This chemical compound is used as a solvent for various materials, including resins, cellulose derivatives, and nitrocellulose lacquers. Its solvent properties make it a versatile component in the production of coatings, adhesives, and other industrial products.
Used in Polymer Production:
(1S)-(+)-Dimethyl succinate has potential applications in the production of polymers. Its chemical structure allows it to be integrated into polymer chains, contributing to the development of new materials with specific properties for various applications.
Used in Organic Synthesis:
As a chemical building block, (1S)-(+)-Dimethyl succinate is instrumental in organic synthesis. It is used in the construction of complex organic molecules, facilitating advancements in chemical research and the creation of novel compounds for diverse applications.

InChI:InChI=1/C24H42O4/c1-15(2)19-9-7-17(5)13-21(19)27-23(25)11-12-24(26)28-22-14-18(6)8-10-20(22)16(3)4/h15-22H,7-14H2,1-6H3/t17-,18-,19+,20+,21-,22-/m0/s1

Upstream product

• 108-30-5 succinic acid anhydride 
• 2216-51-5 (-)-menthol 
• 110-15-6 succinic acid 
• 543-20-4 succinoyl dichloride 
• 23283-97-8 (+)-(1S,2R,5R)-isomenthol 
• 15356-60-2 (1S,2R,5S)-(+)-menthol 

Downstream Products

• 96055-60-6 (3S,4S)-3,4-bis-(-)-menthyloxycarbonyl-1-methylidenecyclopentane 

Relevant academic research and scientific papers

Development of effective bidentate diphosphine ligands of ruthenium catalysts toward practical hydrogenation of carboxylic acids

Hydrogenation of carboxylic acids (CAs) to alcohols represents one of the most ideal reduction methods for utilizing abundant CAs as alternative carbon and energy sources. However, systematic studies on the effects of metal-to-ligand relationships on the catalytic activity of metal complex catalysts are scarce. We previously demonstrated a rational methodology for CA hydrogenation, in which CA-derived cationic metal carboxylate [(PP)M(OCOR)]+ (M = Ru and Re; P = one P coordination) served as the catalyst prototype for CA self-induced CA hydrogenation. Herein, we report systematic trial- and-error studies on how we could achieve higher catalytic activity by modifying the structure of bidentate diphosphine (PP) ligands of molecular Ru catalysts. Carbon chains connecting two P atoms as well as Ar groups substituted on the P atoms of PP ligands were intensively varied, and the induction of active Ru catalysts from precatalyst Ru(acac)3 was surveyed extensively. As a result, the activity and durability of the (PP)Ru catalyst substantially increased compared to those of other molecular Ru catalyst systems, including our original Ru catalysts. The results validate our approach for improving the catalyst performance, which would benefit further advancement of CA self-induced CA hydrogenation.

RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND

The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.

Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors

Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.

PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS

The invention relates to a compound of formula (I), wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as cannabinoid 2 preferential agonist.

Asymmetric induction via metalation of succinic esters and amide using S(+) menthol and R(+) 1-Phenylethylamine as chiral auxiliaries

The synthesis of chiral esters and amides with the involvement of asymmetric induction by using pure chiral auxiliaries such as (1S, 2R, 5R) menthol and L-(+)-1-phenylethylamine is described. The chiral mono, di menthol esters and mono amides of succinic acid were synthesized in good yields. These esters and amides were then subjected to metalation and quenched with different alkyl halides to get α substitution to generate a new chiral center.

CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a piperazine ring and a

Process for making monomenthyl esters

A process for making monomenthyl esters of dicarboxylic acids is disclosed. Menthol reacts with a saturated, cyclic anhydride in the presence of a base catalyst under conditions effective to produce a mixture of mono- and bis-menthyl esters in which the molar ratio of mono- to bis-menthyl esters is enhanced compared with the ratio of esters produced in a similar uncatalyzed process.

Cyclopropane PNA: Observable triplex melting in a PNA constrained with a 3-membered ring

The first peptide nucleic acid (PNA) with a cyclopropane in the backbone has been synthesized, and the effects of the ring on DNA/RNA binding properties of the PNA have been examined. Well-defined triplex to duplex melting transitions of PNA2 DNA complexes is clearly observed by variable temperature UV absorbance with the cyclopropane-constrained PNA.

Halothenoyl-cyclopropane-1-carboxylic acid derivatives

Compounds of formula (I) wherein R is hydroxy, linear or branched C1-C6 alkoxy, phenoxy, benzyloxy, a group -N(R1R2) wherein R1 is hydrogen, linear or branched C1-C4 alkyl, benzy

Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid

The compounds of formula I: ???wherein R is a glycoside residue optionally having one or more hydroxy groups alkylated or acylated by C1-C4 alkyl or acyl groups, are long lasting inhibitors of kynurenine 3-monooxygenase (KMO) and potent glutamate (GLU) re